Open Access Highly Accessed Pre-publication history

A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial

Clemens Giessen, Ludwig Fischer von Weikersthal, Axel Hinke, Sebastian Stintzing, Frank Kullmann, Ursula Vehling-Kaiser, Julia Mayerle, Markus Bangerter, Claudio Denzlinger, Markus Sieber, Christian Teschendorf, Jens Freiberg-Richter, Christoph Schulz, Dominik Paul Modest, Nicolas Moosmann, Philipp Aubele and Volker Heinemann*

BMC Cancer 2011, 11:367  doi:10.1186/1471-2407-11-367

Pre-publication versions of this article and reviewers' reports

Original Submission - Version 1 Manuscript 28 Mar 2011
Reviewer's Report Stephen Clarke 05 Jul 2011
Resubmission - Version 2 Manuscript Author's comment 29 Jul 2011
Editorial acceptance 16 Aug 2011
Published 23 Aug 2011